MarketsandMarkets forecasts the market will grow from $5.43 billion in 2026 at a 12.0% CAGR, driven by biologics manufacturing, CDMO outsourcing, perfusion processing and demand from cell and gene therapy production.
MarketsandMarkets said the global single-use bioreactors market is projected to rise from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, representing a 12.0% CAGR. The report said demand is being supported by expanding investment in biologics, biosimilars, vaccines, recombinant proteins, viral vectors, and cell and gene therapies, along with broader adoption of flexible and closed biomanufacturing systems. The firm said single-use bioreactors are being used across cell line development, seed-train expansion, process optimization, clinical production, and commercial manufacturing. Their appeal is tied to reduced cleaning requirements, faster changeovers, lower contamination risk, and suitability for multiproduct facilities, supporting uptake among pharmaceutical and biotechnology companies, CDMOs, CROs, and research institutes. MarketsandMarkets said North America held the largest regional share at 37.9% in 2025, while the single-use bioreactor systems segment accounted for the largest product share at 48.1%. Within systems, the 501–1,500 L category led in 2025, reflecting use in clinical- and commercial-scale production of monoclonal antibodies, recombinant proteins, vaccines, and biosimilars. The cell and gene therapy segment is expected to post the fastest growth by molecule type at 14.2% during the forecast period. By process mode, the report said perfusion/continuous systems are expected to record the highest CAGR at 13.8%, driven by demand for intensified and high-cell-density bioprocessing. MarketsandMarkets said the shift toward integrated, higher-capacity and digitally connected platforms is also being shaped by automation, advanced sensors, process analytics, improved film materials, supply-chain resilience and sustainability considerations. Key companies named in the report include Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Avantor, Inc., Repligen Corporation and Lonza.